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ABSTRACT 
 
Background. Pulmonary embolism (PE) is a potentially fatal but treatable disease. Secondary 
prophylaxis is usually continued for three to six months, but the risk for recurrence or death lasts at 
least for one year. Knowing the clinical course of 1-year anticoagulated patients and identifying risk 
factors for adverse events may be of high clinical relevance.  
Objective. To investigate the incidence of recurrence, mortality and bleeding in PE patients 
anticoagulated for 1 year and to identify risk factors for such adverse events. 
Design. We evaluated prospectively for 1 year all consecutive in- and out-patients with a final 
diagnosis of acute PE referred to a single centre in Pisa, Italy, in the years 2001-2005. No exclusion 
criteria were adopted. 
Results. Out of the original 497 patients, 136 (27.4%) died before completing the 1-year follow-up, 
36 (26.5%) because of PE. Of them, 31 (86.1%) did it within 10 days of diagnosis. Risk factors for 
death were presence of idiopathic PE (0.003), of persistently severe dyspnea in spite of treatment 
(0.002), of high perfusion defect score index ( PDI ). Risk of death increased proportionally when 
persistently severe dyspnea and high PDI were contemporary present. Recurrence occurred in 48 
(9.6%) cases, 39 (81.2%) within 10 days of diagnosis. The 1-year fatality rate was 74%, the 10 days 
79%. Risk factors for recurrence were persistently severe dyspnea (0.007), high PDI (0.003), 
cardiac or pulmonary comorbilities (0.005). 
Bleeding occurred in 17 (3.4%) cases and was major in 1 (0.2%); most cases (70.6%) occurred 
between 30 and 180 days, no case was observed after 180 days. No risk factor could be identified as 
associated to bleeding. 
Conclusions. In patients anticoagulated and carefully followed for one year, death occurred in more 
than a quarter of cases, a quarter of them because of PE;  the vast majority did it in the first 10 days. 
Recurrence occurred in one every ten patients, again early. Persistently severe dyspnea and high 
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PDI were risk factors for both mortality and recurrence. Bleeding was rare and minor and no case 
was observed after 180 and 360 days of treatment. 
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The risk for fatal pulmonary embolism, 
recurrence, and bleeding in patients 
undergoing 1-year anticoagulation for PE. 
 
The clinical course of 1-year anticoagulated pulmonary embolism: results of a 
prospective, cohort study. 
 
 
 
 
BACKGROUND 
 
Pulmonary Embolism (PE) is a potentially fatal disease for which treatments are effective, though 
not free from risk.
1-5
 After the acute event, efforts must be made to prevent fatal and nonfatal 
recurrencies; to this end, the knowledge of the natural history of PE may be of help. Insofar, most 
papers reported results of the 3-months-risk for recurrence, mortality, and bleeding,
6-10
 other 
reported on the clinical course of PE until one year or more in patients in whom the anticoagulation 
was withdrawn after 3 or 6 months
11-12 
or was not defined since left to the discretion of the attending 
physician.
13-15
 
Few data are available in patients anticoagulated for longer time, though it is known that the risk of 
recurrent fatal and non fatal PE is present even far from the acute event, namely during the first year 
from diagnosis.
12,14,16
 Moreover, Agnelli et al showed that a clinical benefit was associated with 
extending the duration of anticoagulant therapy to one year in patients with idiopathic DVT 
17
 and in 
those with a first episode of PE;
18
 however, they did not identify risk factors for recurrence, bleeding 
and PE mortality during such period of time.  
Therefore, we evaluated prospectively all the consecutive patients affected by PE with the purpose 
of giving novel insight in terms of recurrence, mortality and bleeding, both early after diagnosis and 
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lately during the whole 1-year-follow-up period under oral anticoagulant treatment. Also, we used 
the multivariate analysis in order to identify and quantify the relative risk of the above adverse 
events during the follow-up. 
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AIMS 
We evaluated the clinical outcome during one year in a large
 
group of consecutive patients with PE. 
We aimed to assess the
 
incidence of recurrent VTE, mortality, and bleeding complications
 
in 
patients with PE and treated with oral anticoagulants during
 
this follow-up period. Second, we 
aimed to identify risk factors
 
for recurrence, bleeding, and mortality, and to determine the
 
time 
course of these events within one year of the start of
  
treatment.
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MATERIALS AND METHODS 
 
Study design 
We followed prospectively all the consecutive patients who had a final instrumental diagnosis of PE 
made at the Cardio-Thoracic Department of the University of Pisa during the period may 1
st
 2001 - 
may 31
st
 2005; therefore, patients were enrolled in a single academic center for diagnosis and 
treatment of venous thromboembolism. All patients were anticoagulated for at least 12 months 
independently on the origin of PE, since this has been our policy since 1969. No exclusion criteria 
to enter the study was established, in order to remain as adherent as possible to real life conditions; 
thus, patients with active cancer, permanent immobility, or in anticoagulant prophylaxis before PE 
were included. 
Both in and out patients were included. Inpatients were defined as those who showed symptoms 
compatible with the disease while they were in the hospital for reasons different from PE. Out 
patients were defined as those who came to the Emergency Department right because symptoms 
compatible with PE. Furtherly, patients were divided according to risk factors as having secondary 
PE in presence of 1 or more transient risk factors and idiopathic PE in absence of any of them. 
The protocol was approved by the institutional review board for human studies. 
 
Acute embolization 
All patients underwent perfusion lung scan (PLS): when it was normal or abnormal but not 
compatible with PE and clinical probability was low, PE was excluded.
19-20
 In the remaining cases, 
diagnosis was made by a positive spiral CT 
21
 or a positive pulmonary arteriography
19
. CT 
instrument was located in the emergency department and dedicated to the emergencies only. When 
this examination was not promptly available or contraindicated due to hypersensitivity to contrast 
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medium or renal failure the diagnosis was made or excluded in presence of concordant results of 
perfusion scintigraphy and clinical probability.
19-20
 
Perfusion lung scintigraphy was obtained according to a previously described method.
22  
Ventilation 
lung scan was not performed.
22
 Perfusion lung scintigraphy was read for the detection of unperfused 
lung segments (ULSs) and graded in the following way: a score of 1 was assigned to each 
unperfused area with the size, shape and location of a known lung segment; and a score of 0.5 was 
assigned to perfusion defects with subsegmental size, shape, and location or when a scintigraphic 
region corresponding to a lung segment was poorly perfused. The number of ULSs was taken as an 
index of the severity of PE (Perfusion Damage Index, PDI).
22
 Perfusion lung scintigraphy was 
examined by two independent observers and the degree of agreement was tested.  
Chest spiral CT images have been acquired with a four-slices multidetector-row CT.
23
 The 
examination consisted of an evaluation of the pulmonary arteries up to and including the 
subsegmental vessels. The patient were examined during a breath hold or shallow breathing. The 
acquisition parameters for multidetector-row CT were injection of a total volume of 100 to 120 ml 
of non-ionic contrast material; imaging 9 to 20 seconds after initiation of the contrast-material 
injection; scanning perfomed at 1.0 to 1.3 mm per section with a pitch of 1.25 to 1.75, 120 kV, and 
115 to 260 mA; and reconstruction of  images at 0.6 to 0.8 mm intervals.   
Pulmonary angiography was obtained according to standardized procedures.
19
 
All patients were investigated for chest pain, dyspnea, presence of syncope, presence of acquired 
predisposing factors. Dyspnea was subsequently divided in mild, moderate, severe; moreover, we 
introduced  the new definition of persistently severe dyspnea as “the one that did not improve 24 
hours of the onset of treatment”. Acquired predisposing factors were: immobilization for longer 
than 7 consecutive days, major surgical procedure, bone fracture of the lower extremities, history of 
lower deep vein thrombosis (DVT), or any prior episode of PE (if the patient had at any time 
documented episodes of DVT or PE that required anticoagulant therapy), estrogen use (defined as 
use of estrogen containing drugs within the past 3 months), and postpartum period (defined as the 
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presence of pregnancy within the past 3 months), neoplastic disease. All neoplasms were included 
independently from disease activity or medical treatment. Also, pre-existing cardiac or respiratory 
disease were taken into considerations as follows: coronary artery disease, hypertensive 
cardiomiopaty, valvular cardiomiopaty, heart failure (right, left or both), COPD, bronchiectasis, 
interstitial lung disease. 
 
Follow-up  
All patients were followed by the authors until death, lost from follow-up or 31th may, 2006, 
whichever came first. Patients were anticoagulated for a period variable within 5 and 10 days with 
unfractioned heparin monitored by aPTT in most cases; rarely, patients were assigned to low-
molecular-weight heparin. In all cases, heparin was followed by oral anticoagulation monitored by 
the INR (between 2 and 3) at least until 12 months after the acute episode. Patients were regularly 
followed in the anticoagulation clinic to optimize the oral treatment.  
A clinical follow up was performed directly when patients were in hospital, by ambulatory visits 
every 3 months or by phone calls at predetermined times in dismissed patients. Moreover, all 
patients were scheduled for a scintigraphic and blood gas follow-up at 7, 30 and 365 days after the 
acute episode, to investigate the recovery of pulmonary perfusion or the possible recurrence of 
asymtomatic PE. By definition all deaths occurring during hospitalization with symptoms highly 
suggestive of PE were considered as due to recurrence. Recurrences were divided in two categories, 
according to a model reported recently
12
 tat we slightly modified: a) definite or probable fatal PE if 
it was confirmed at autopsy, or it was preceded in the immediate period before death by confirmed 
nonfatal PE, or if patients died during hospitalization with symptoms highly suggestive of PE; 
possible fatal PE when patients died after hospitalization with symptoms highly suggestive of PE as 
reported by the attending physician; b) definite or probable non fatal PE if new perfusion defects 
were detected on a scintigraphic follow-up predefined at 7, 30, 360 days of the acute episode or 
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extraordinarily made because of new-onset symptoms; possible non fatal PE if patients reported 
symptoms compatible with recurrence at the clinical follow-up. 
Bleedings were sought in all hospitalized patients, at the time of ambulatory visits or by telephone 
calls when dismissed. Bleedings where categorized as major and minor. We classified as major the 
following: fatal (death due to haemorrhage), intracranial (documented by imaging), intra-abdominal, 
required surgery or angiographic intervention and if bleeding led to haemoglobin reduction of 2g/dL 
or more and/or needed transfusion. Minor bleedings were considered all those not fulfilling criteria 
for major bleedings. 
 
Statistical Analysis 
Continuous variables were expressed as mean ± 1 SD and categorical variables as percentages.  
The duration of follow-up was expressed in days. We considered clinical outcomes that occurred 
during follow-up from the time of recruitment until death or the end of patient follow-up. The 
primary end points were the occurrence of definite or probable fatal PE, definite or probable 
recurrences, bleedings. To standardize for different lengths of follow-up in the cohort, we used the 
annual risk for definite or probable fatal PE (the number of fatal events per 100 person-years of 
follow-up). The case-fatality rate for definite or probable fatal PE was calculated as follows: definite 
or probable fatal PE / (definite or probable fatal PE + any nonfatal PE). We used the Kaplan–Meier 
method to determine the time course of events. 
The predictors of event-free survival were identified by univariate and multivariate analysis 
performed using the Cox proportional hazards regression model. Categorical variables were 
included into the model as dummy variables. The independent predictors of event-free survival were 
identified using a backward elimination procedure in a multivariate Cox regression analysis. Once 
the independent predictors of event-free survival were identified, interaction terms among these 
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predictors were also entered into the Cox proportional hazards regression model to evaluate if they 
also acted as effect modifiers.  
To assess the prognostic value of the final Cox proportional hazards regression models we used the 
time-dependent ROC curve estimation from censored survival data using the Nearest Neighbor 
Estimation method.
24
 The linear prognostic scores obtained from the final Cox models were 
considered in the analysis. The area under the time-dependent ROC curves was used as prognostic 
accuracy  of the models.   
All statistical tests were two-tailed; a p <0.05 was considered as significant. Statistical analysis was 
performed with commercially and free available software (SPSS 10.0, SPSS Inc., Chicago, Illinois, 
USA; R: A Programming Environment for Data Analysis and Graphics, Version 2.7.1, R 
Foundation for Statistical Computing, Vienna, Austria). 
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RESULTS 
 
Among 1027 patients referred with the suspicion of PE, 497 (48.4%) had a final diagnosis of PE. In 
particular, 415 (83.5 %) were diagnosed by spiral CT, 4 (0.80 %) by pulmonary arteriography. In a 
further group of 78 (15.7 %) with abnormal basal perfusion scintigraphy in whom spiral CT or 
arteriography were contraindicated or not available promptly, the diagnosis was confirmed by the 
concordance of lung scintigraphy compatible with PE and high clinical probability.
19 
Basal 
characteristic of 497 patients are reported in table 1.  
Table 1.  Baseline Characteristics of the 497 Patients With PE N ( % ) 
Inpatients 281 (61.8 %) 
Age** 68.9 ( 17-95 ) 
Age<60 104 ( 20.9 ) 
60≤Age<70 120 ( 24.1 ) 
Age>70 273 ( 54.9 ) 
Male gender 223 ( 44.9 ) 
Smokers 48 ( 9.9 ) 
Previous smokers 131 ( 26.9 ) 
Idiopathic PE 212 ( 42.7 ) 
Risk factors  
Cancer 127 ( 25.6 ) 
Surgery 164 ( 33.0 ) 
Immobilization > 7days 179 ( 36.0 ) 
Estrogen use ( on 274 female ) 15 ( 5.5 ) 
Previous PE 35 ( 7.0 ) 
Previous DVT 40 ( 8.4 ) 
DVT 172 ( 36.2 ) 
Vasculitis 2 ( 0.4 ) 
Cardiopulmonary Comorbilities  
Previous cardiopulmonary disease 191( 38.4 ) 
Symptoms  
Dyspnea  310 ( 66.0 ) 
Persistent Dyspnea 58 ( 12.3 ) 
Syncope 71 ( 15.4 ) 
Arterial blood gas analysis and Perfusion parameters mean ± sd/ N(%) 
pH 7.5 ±  0.05 
PaO2 67.2 ± 15.0 
PaO2st 55.5 ± 17.6 
PaCO2 33.4 ± 6.6 
PDI 4.7 ± 2.5 
PDI ≥ 6 148 (29.8 %) 
** Age is presented as mean ( range )  
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Among them,  281  (61.8 %) were inpatients. Mean age was 68.9 years with a prevalence of 
subjects of female sex (55,1%). Among the risk factors, surgical procedures (33.0 %),  cancer (25.6 
%) and cardiopulmonary comorbilities (38.4%) were the most represented. In 212 patients (42.7 %) 
no identified risk factor was found and PE was classified as idiopathic. Dyspnea was the most 
frequent symptom (313 cases, 63%) and, most relevant, persistently severe dyspnea was present in 
60 cases (12.1%). 
Patients showed an average perfusion impairment of 26.1% of the entire vascular bed (PDI 4.7+ 
2.5). Moreover, 148 (29.8%) patients had a PDI greater than or equal to 6 unperfused lung 
segments, that represents 30% of the entire vascular bed. This value was therefore arbitrarily taken 
as the threshold above which the perfusion impairment may be considered as severe. No significant 
difference was found between the two readers as for the entity of lung scintigraphic impairment 
(p>0.5).  
Among 497 patients, 172 (36,2 %) had DVT in adjunct to PE, as demonstrated on instrumental 
examination, 40 (8.4%) reported a previous episode of  DVT. 
 
Recurrence and death 
Among the original 497 patients, 361 (72.6 %) completed the 1-year-follow-up while 136 (27.4 %) 
patients died before completing it. In further details, 36 (26.5%) patients died because of recurrent 
PE, 59 (43.4%) due to neoplasms, 20 (14.7%) to cardiac and 21 (15.4%) to pulmonary causes.  
We recorded 48 (9.6%) recurrences among all patients; of them 39 (81.2%) occurred early within 10 
days of diagnosis and 9 lately during 1 year. Definite or probable fatal PE occurred in 31 (65%) 
cases, all within 10 days of diagnosis (Fig. 1); possible fatal PE in 5 (10%) cases that occurred 
sparsely after discharge during the following period until 1 year. Annual risks for fatal PE was 
9.4/100 person/years. The case-fatality rate for PE was 75% (31/48) when considered during the 
whole 1-year-follow-up, it was 79% (31/39) when deaths occurred during the first 10 days. Probable 
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non fatal PE occurred in 10 (21%) cases, two of them found casually at the scintigraphic follow up, 
possible in 2 (4%). 
 
 
Risk factors for recurrence and death 
Risk factors for both early and late recurrences were the presence of a persistently severe dyspnea 
(p=0.007), of a high PDI (p=0.003) and of cardiac or pulmonary comorbilities (p=0.005) (table 2). 
 
 
Table 2. Risk factors for  definite or probable recurrences  
  Recurrence No Recurrence Univariate Analysis Multivariate Analysis 
Variables            48             449 p HR (95 % ICI) p HR (95 % ICI) 
  N ( % )/means±sd  N ( % ) /means±ds        
Inpatients  27 (60.0) 254 (62.0) 0,815 0.93 (0.51-1.69)   
Age  69.6 ± 14.5  68.8 ± 14.1 0.702 1.00 ( 0.98 - 1.02 )   
Male gender  17 ( 35.4% ) 206 ( 45.9% ) 0,191 0.67 ( 0.37 - 1.22 )   
Idiopathic PE  25 ( 52.1 ) 187 ( 41.6 ) 0,185 1.47 ( 0.83 – 2.58 )   
Risk factors  
Surgery  12 ( 75.0 ) 152 ( 33.9 ) 0,228 0.67 ( 0.35 - 1.28 )   
Cancer  8 ( 16.7 ) 119 ( 26.5 ) 0,194 0.60 ( 0.28 - 1.29 )   
Immobilization > 7days  17( 35.4 ) 162 ( 36.1 ) 0.928 0.97 ( 0.54 – 1.76 )   
Previous PE  3 ( 6.3 ) 32 ( 7.1 ) 0,821 0.87 ( 0.27 – 2.81 )   
DVT  14 ( 29.2 )  158 ( 37.0 ) 0,223    0.67 ( 0.36-1.27 )   
Previous DVT  3 ( 6.3 ) 37 ( 8.7 ) 0.429      0.62(0.19-2.03)   
Cardiopulmonary Comorbilities  
Previous Cardiopulmonary 
disease 
 33( 68.8 ) 158 ( 35.2 ) 0,000 3.80 ( 2.06 – 7.00 ) 0.005 2.59 (1.34-5.02) 
Symptoms             
Dyspnea  29( 60.4 ) 284( 63.3 )  0,227 1.66 ( 0.73 – 3.79 )   
Persistent Dyspnea  12 ( 25.0 ) 48 ( 10.7 ) 0,005    3.83 ( 1.51-9.73) 0.007 3.64 (1.42-9.37) 
Syncope  5 ( 10.4 ) 66 ( 14.7 ) 0,447  0.70 ( 0.28 – 1.76 )   
Arterial blood gas analysis and Perfusion parameters  
   means±sd/N (%) means±sd/N (%) p  p HR ( 95% C.I. ) 
pH  7.46±0.04 7.46±0.05 0,602 0.17 ( 0.00-126.5 )   
PaO2  68.7±12.4 67.0±15.2 0,524 1.01  ( 0.99-1.03 )   
PaO2st  58.5±14.4 55.2±17.9 0,284 1.01 ( 0.99-1.03 )   
PaCO2  34.0±4.2 33.4±6.8 0,585 1.01 ( 0.97-1.05 )   
PDI  6.2±2.3 4.5±2.4 0,000 1.24 ( 1.12-1.37 ) 0.003 1.18(1.06-1.31) 
PDI ≥ 6  31 ( 64.6 ) 117 ( 26.1 ) 0,000 4.71 ( 2.60-8.51 )   
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Risk factors for overall PE death were the presence of idiopathic PE (p=0.003), of a persistently 
severe dyspnea (p=0.002) and of a high PDI (p=0.000) (table  3).  
 
 
 
 
Table 3. Risk factors for definite or probabile fatal PE  
  Patients died due 
to PE 
Living 
patient/patient 
died due to others 
disease 
Univariate Analysis Multivariate Analysis 
Variables            36             461 p HR (95 % ICI) p HR (95 % ICI) 
 
 
N ( % )/means±sd  N ( % ) /means±ds         
Inpatients  20 (55.5) 261 (56.6) 0.892 0.95 (0.47-1.91)   
Age  70.0 ± 14.9 68.81 ± 14.3 0.616 1.01 ( 0.98 - 1.03)   
Male gender  15 ( 41.7% ) 208 ( 45.1% ) 0.714 0.88 ( 0.45 - 1.71 )   
Idiopathic PE  22 ( 61.1 ) 190 ( 41.2 ) 0.028 2.12 ( 1.08 - 4.15 ) 0.003 2.11 ( 1.07 - 4.15 ) 
Risk factors  
Surgery  8 ( 22.2 ) 156 ( 33.8 ) 0.166 0.57 ( 0.26 - 1.26 )   
Cancer  6 ( 16.7 ) 121 ( 26.2 ) 0.264 0.61 ( 0.25 - 1.46 )   
Immobilization > 7days  11( 30.6 ) 168 ( 36.4  ) 0.487 0.78 ( 0.38- 1.58 )   
Previous PE  1 ( 2.8 ) 34 ( 7.4) 0.321 0.37 ( 0.05-2.67 )   
DVT  9( 25.0 )  163 ( 37.1 ) 0.109 0.54 ( 0.25-1.15 )   
Previous DVT  2 ( 5.6 ) 38 ( 8.2 ) 0.249      0.51(0.12-2.16)   
Cardiopulmonary Comorbilities  
Previous 
Cardiopulmonary disease 
 
 
24( 66.7) 
 
167 ( 36.2 ) 
 
0.001 
 
3.39 ( 1.69 – 6.78 ) 
  
Symptoms 
 
            
Dyspnea  19 (52.8) 294( 63.8 )  0.861   1.08 ( 0.45 – 2.57 )   
Persistent Dyspnea  10 (27.8) 50 ( 10.8 ) 0.020 3.15 ( 1.20-8.29 ) 0.002 3.55 ( 1.33-9.45 ) 
Syncope  4 (11.1) 67 ( 14.5 ) 0.593 0.75 ( 0.27 – 2.13 )   
Arterial blood gas analysis and Perfusion parameters  
   
means±sd/N (%) means±sd/N (%) p HR ( 95% C.I. ) p HR ( 95% C.I. ) 
pH  7.46±0.04 7.46±0.05 0.959 0.81 ( 0.00-2247 )   
PaO2  66.6±12.9 67.2±15.1 0.997 1.00  ( 0.97-1.02 )   
PaO2st  56.0±14.8 55.4±17.8 0.858 1.00 ( 0.98-1.02 )   
PaCO2  34.32±4.78 33.4±6.7 0.692 1.01 ( 0.96-1.06 )   
PDI  6.5±1.9 4.5±2.4 0.000 1.29 ( 1.15-1.44 ) 0.000 1.30 ( 1.16-1.46 ) 
PDI ≥ 6  27 ( 75.0 ) 121 ( 26.2 ) 0.000 7.66( 3.60-16.29 )   
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When looking for risk factors for early death only, we found the presence of a persistently severe 
dyspnea (p=0.012) and of a high PDI (p=0.000) (table 4).  
 
 
 
Table 4. Risk factors for early definite or probabile fatal PE  
  Patients died 
due to early PE 
Living 
patient/patient 
died due to 
others disease 
Univariate Analysis Multivariate Analysis 
Variables            31             466 p HR (95 % ICI) p HR (95 % ICI) 
  N ( % )/means±sd  N ( % ) /means±ds        
Inpatients  20 (60.6) 261 (61.8) 0,789 1.11 (0.51-2.41)   
Age  70.0 ± 14.9 68.81 ± 14.3 0.661 1.01 ( 0.98 - 1.03 )   
Male gender  15 ( 41.7% ) 208 ( 45.1% ) 0,747 0.89 ( 0.44 - 1.81 )   
Idiopathic PE  22 ( 61.1 ) 190 ( 41.2 ) 0,080 1.89 ( 0.93 – 3.86)   
Risk factors  
Surgery  8 ( 22.2 ) 156 ( 33.8 ) 0,385 0.70 ( 0.31 - 1.56 )   
Cancer  6 ( 16.7 ) 121 ( 26.2 ) 0,230 0.56 ( 0.21 - 1.45)   
Immobilization > 7days  11( 30.6 ) 168 ( 36.4  ) 0.950 0.98 ( 0.47 – 2.04 )   
Previous PE  1 ( 2.8 ) 34 ( 7.4) 0,406 0.43 ( 0.06 – 3.15 )   
DVT  9( 25.0 )  163 ( 37.1 ) 0,144 0.55 ( 0.24-1.23 )   
Previous DVT  2 ( 5.6 ) 38 ( 8.7 ) 0.233  0.29 (0.04-2.19)   
Cardiopulmonary Comorbilities  
Previous 
Cardiopulmonary disease 
  
24( 66.7) 
 
167 ( 36.2 ) 
 
0,001 
 
3.50 ( 1.65 – 7.44 ) 
  
Symptoms             
Dyspnea  19 (52.8) 294( 63.8 )  0,805 0.89 ( 0.35 – 2.27 )   
Persistent Dyspnea  10 (27.8) 50 ( 10.8 ) 0,060    2.69 ( 0.96 - 7.57) 0.012 3.91 ( 1.35-11.32) 
Syncope  4 (11.1) 67 ( 14.5 ) 0,827  0.89 ( 0.31 – 2.54 )   
Arterial blood gas analysis and Perfusion parameters  
   means±sd/N (%) means±sd/N (%) p  p HR ( 95% C.I. ) 
pH  7.46±0.04 7.46±0.05 0,976 1.14 ( 0.00-4134 )   
PaO2  66.6±12.9 67.2±15.1 0,927 0.999  ( 0.97-1.03 )   
PaO2st  56.0±14.8 55.4±17.8 0,661 1.00 ( 0.98-1.03 )   
PaCO2  34.32±4.78 33.4±6.7 0,492 1.02 ( 0.97-1.06 )   
PDI  6.5±1.9 4.5±2.4 0,000 1.38 ( 1.22-1.55 ) 0.000 1.41 ( 1.25-1.60 ) 
PDI ≥ 6  27 ( 75.0 ) 121 ( 26.2 ) 0,000 17.26 ( 6.04-49.34 )   
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Among the 48 patients who showed recurrences, the risk factors for mortality were the presence of a 
high PDI (p=0.000), of a idiopathic PE (p=0.004) and of neoplasms (p=0.056). The area under the 
time-dependent ROC curves (Fig. 1) showed a good prognostic value of the final Cox models 
(AUC=0.74).  
 
Figure 1. 
 
No significant interaction between predictors of  fatal PE-free survival was observed. Finally, the 
RR for early death increased proportionally when persistently severe dyspnea and high PDI were 
contemporary present. 
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Risk of bleeding  
 
Bleeding occurred in 17 cases (3.4%);  it was classified as major in 1 (5.9%) case. In the whole 
follow-up, bleeding occurred in 1 (5.9%) case in the first 10 days, in 4 (23.5%) cases between 10 
and 30 days, in 12 (70.6%) cases between 30 and 180 days.  No case was observed between 180 and 
360 days. 
No risk factor was identified by Cox regression analysis as associated with bleeding in patients of 
the present series (table 5). 
 
Table 5. Risk factors for Bleeding         Univariate 
  Bleeding No Bleeding Univariate Analysis 
Variables            17             480 p HR (95 % ICI) 
 
 N ( % )/means±sd  N ( % ) /means±ds    
Inpatients  9 (52.9) 272 (56.6) 0,441 0.69 (0.26-1.78) 
Age  72.1 ± 10.5  68.8 ± 14.2) 0.336 1.02 ( 0.98 - 1.06 ) 
Male gender  8 ( 47.1% ) 215 ( 44.8% ) 0,823 1.11 ( 0.43 – 2.89 ) 
Idiopathic PE  9 ( 52.9 ) 203 ( 42.3 ) 0,400 1.50 ( 0.58 – 3.90 ) 
Risk factors 
Surgery  5 ( 29.4 ) 159 ( 33.1 ) 0,733 0.83 ( 0.29 – 2.37 ) 
Cancer  2 ( 11.8 ) 125 ( 26.0 ) 0,275 0.44 ( 0.10 - 1.92 ) 
Immobilization > 7days  7( 41.2 ) 172 ( 35.8 ) 0.668 1.23 ( 0.47 – 3.24 ) 
Previous PE  0 ( 0.0 ) 35 ( 7.3 ) 0,448 0.04 ( 0.00 – 139 ) 
DVT  7 ( 41.2 )  165 ( 36.0 ) 0,658 1.26 ( 0.46-3.47 ) 
Previous DVT  2 ( 11.8 ) 38 ( 8.3 ) 0.590 1.53(0.32-7.21) 
Cardiopulmonary Comorbilities 
Previous 
Cardiopulmonary disease 
 9( 52.9 ) 182 ( 37.9 ) 0,131 2.08 ( 0.80 – 5.40 ) 
Symptoms 
        
Dyspnea  13( 76.5 ) 300( 62.5 )  0,396 1.72 ( 0.49 – 6.04 ) 
Persistent Dyspnea  1 ( 5.9 ) 59 ( 12.3 ) 0,872    0.83 ( 0.09-7.98) 
Syncope  2 ( 11.8 ) 69 ( 14.4 ) 0,801  0.83 ( 0.19 – 3.62 ) 
Arterial blood gas analysis and Perfusion parameters 
   means±sd/N (%) means±sd/N (%) p  
pH  7.46±0.03 7.46±0.05 0,788 0.24 ( 0.00-7032 ) 
PaO2  65.2±12.3 67.2±15.0 0,600 0.99  ( 0.95-1.03 ) 
PaO2st  54.2±18.7 55.5±17.6 0,767 0.99 ( 0.96-1.03 ) 
PaCO2  34.8±9.5 33.4±6.5 0,443 1.02 ( 0.97-1.07 ) 
PDI  4.4±3.5 4.7±2.4 0,916 1.01 ( 0.83-1.23 ) 
PDI ≥ 6  6 ( 35.3 ) 142 ( 29.6 ) 0,433 1.49 ( 0.55-4.03 ) 
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DISCUSSION 
 
We evaluated prospectively the 1-year-clinical and scintigraphic outcome under anticoagulant 
treatment of a large cohort of unselected in and outpatients with confirmed diagnosis of PE, with the 
aim of investigating incidence, timing and risk factors of adverse events.  
Mortality in our patients was as high as 25% after 1 year, causes spanning from neoplasms, to 
cardiopulmonary causes other than PE, to fatal recurrence of PE. This result reproduces strictly the 
overall mortality reported by Carlson et al 
13
 who stopped treatment after 3 or 6 months and had a 
24% one-year overall mortality in patients with PE. Also, the underlying comorbidities were 
similar, being cancer (43.4%) and cardiopulmonary diseases (30.1%) responsible for 73.5% of all 
deaths. Differently from Carlson, however, we found that death related to PE after 1 year occurred 
in about 7% ( versus 2.5% of Carlson) of the original sample of patients, 27% of all patients who 
die. 
 
Since patients in our study were all anticoagulated up to 1 year, the difference could be 
searched in more severe acute pulmonary damage, older age, higher number of in-patients or 
patients with idiopathic PE in our series. The PE-associated mortality rate of  7% during one year is 
lower than the 15% found by
 
van Strijen and colleagues
7
, who stopped follow-up (and the therapy)  
at 3 months; it is instead consistent with the 7.7% found in a study by Perrier et
 
al
23
 that also 
concluded the follow-up after 3 months. Comparison with both studies seem to underline the 
maximum risk of death in the early phases; however, our study only allows to define the risk that a 
population of both in and out-patients has during a one-year anticoagulant treatment. Although most 
frequently in the early phases of disease (86% of cases died during the first 10 days of the 
embolization), death due to PE may also occur later, in spite of an appropriate treatment. This 
underlines the necessity of a early diagnosis and prompt therapy, as well as the need for the 
knowledge of the early and late risks for fatal PE in each single patient.  
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We found that risk factors for early mortality were severity of PE as evaluated on perfusion lung 
scintigraphy and persistently severe dyspnea while presence of idiopathic PE represents a further 
late risk factor. Severity of disease has previously been described as associated to the mortality of 
PE
14
 in adjunct, however, we demonstrated in the current study that this parameter is of great 
importance also beyond the acute event keeping its value during the whole follow-up. This 
underline the utility of a simple method to quantify the severity of the damage extension. The 
persistence of severe dyspnea in spite of the anticoagulant treatment is a powerful risk factor for 
fatal PE, both in the acute and in the late phases of the disease. Patients complaining this frequent 
symptom (12.1% of all patients included and 27.8% of patients who died because of PE) have as 
much as three and half times increased probability of dying because of fatal PE. Furthermore, this 
symptom increases disproportionally the risk for death in relation to the extension of pulmonary 
perfusion damage. Indeed, the presence of severe persistent dyspnea makes the risk 3.5 times 
greater in patients with 6 unperfused segments, 7 times greater when the damage corresponds to 14 
unperfused segments. A simple formula to calculate the risk may easily be available. A third risk 
factor for fatal PE is represented by the idiopathic origin; though this was already known, we 
defined the risk in as much as more than twice. Considering that in our series the amount of patients 
affected by idiopathic PE was more than  40% of the total, it is easy to understand the relevance of 
such variable. The reason for which it plays a role in the late phases of disease is unclear, but it is 
hypothesizable that the idiopathic origin includes other risk factors largely unknown, whose 
influence may be played at any time. 
The recurrence rate of 9.6% is similar to that observed in most cohort studies.
13-14 
Carson et al had 
33 patients out of a total of 399 (8.3%) with clinically apparent recurrence of PE in the year of 
follow-up, Miniati et al 30 out of 320 (9.4%). In a recent Dutch study, instead, such a percentage 
was much lesser (20 patients over 673, 3%); however, in this case they stopped prophylaxis and 
follow-up 3 months of the acute PE. The
 
discrepancy might be due to a different
 
comorbidity profile 
with a higher prevalence
 
of cardiovascular disease, a greater number of older, in-patients in our 
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series, and the systematic performance of a scintigraphic follow-up which has been able to identify 
new perfusion abnormalities in 2 asymptomatic patients.  
Recurrencies occurred early (within 10 days) in at least 80% of cases and often they were fatal. 
Indeed, the case fatality
 
rate for PE in the current study was 75% when considered during the whole 
1-year-follow-up, it was 79% when deaths occurred during the first 10 days. Risk factors for early 
recurrences are again persistently severe dyspnea and severity of PE; later on, presence of 
cardiopulmonary comorbidities joins the previous two risk factors in determining recurrences. Our 
results appear rather different from them of an earlier study
9
 in which the presence
 
of cancer, 
chronic cardiovascular disease, chronic respiratory
 
disease, and other clinically significant diseases 
were risk factors for recurrent VTE in patients with PE. 
  
We found clinically most useful to know that the first 10 days represent the most critical period for 
recurrences, that the case fatality rate of recurrences is high and even higher in the early phases, and 
that the knowledge of risk factors (specifically massive damage on perfusion scan, severe persistent 
dyspnea and idiopathic origin of PE) might help in more rigorous monitoring and more aggressive 
therapy. Also, it appears relevant that risk factors for mortality among patients with recurrences 
(severity of PE, idiopathic origin, presence of neoplasms) may be known since the patient' 
presentation; this should alert physicians on how and where to treat patients with such risk factors. 
Likewise it seems of interest to know that the risk of recurrences drops after the acute embolization 
but it is still present months later in spite of an appropriate treatment. 
Bleeding occurred in 17 cases (3.4%); it was classified as major in 1 (0.2%) case since it occurred 
as intracranial bleeding. However, neither this patient or any other  died of bleeding. In the whole 
follow-up, bleeding occurred in 1 (5.9%) case in the first 10 days, in 4 (23.5%) cases between 10 
and 30 days, in 12 (70.6%) cases between 30 and 180 days, none thereafter. Our  bleeding figures in 
the first 3-6 months were similar to those of other studies;
9,11
 no comparison is obviously possible 
with such studies after 6 months. No  risk factor was identified as associated with bleeding in 
patients of the present series of patients. Njkeuter et al
9
  found association with cancer, COPD, 
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being an inpatient; a recent paper from the RIETE registry
25
 has demonstrated that a risk score 
based on 6 variables (recent bleeding, abnormal creatinine level, anemia, cancer, age >75, 
pulmonary embolism at baseline) can identify VTE patients at risk at entry. This of course may help 
in therapeutic decisions. Interestingly enough, no case of bleeding occurred in our patients from 6 to 
12 months from incidental PE. The
 
reason for this might be searched in the careful monitoring of 
patients in the 3-months ambulatory visits and in the effectiveness of anticoagulation clinic; 
moreover, the stabilization of therapy after the initial period and the learning capacity of patients 
and their familiars may have contributed to this excellent result. This occurred in spite of the high 
percentage of patients aged more than 70 years (54.9%), of high amount of inpatients (61.8%), of 
the highly incidence of risk factors for bleeding at the entry, such as cancer (25.6%), surgery 
(33.0%), prolonged immobilization (36.0%). Although we do not have a control group of patients in 
whom the anticoagulant therapy was withdrawn after 3 or 6 months, it seems reasonable to state that 
prolonging anticoagulation until 1 year is certainly safe. Moreover, it appears rather effective.  
 
Limitations 
We are aware that the study suffers some limitations. We included only patients with a certain 
diagnosed of PE and therefore patients in whom emboli were never diagnosed were missed. Our 
follow-up period is limited to one year; however, the recurrence of PE after one year is less 
frequent, as demonstrated by other recent papers
14,26-28
 and the detection of pulmonary hypertension 
that is more frequent beyond a year was not among the aims of our work. Furthermore, we cannot 
demonstrate definitely that prolonging anticoagulation up to 1 year is cost-effective since we do not 
have a control group in which therapy had stopped after 3 or 6 month of the embolization. However, 
this has been our satisfactory policy since more than thirty years and, thus, the data that we report 
represent what happens in real life.  
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CONCLUSIONS 
 
Several points make our study unique. First, all consecutive patients with definitive diagnosis of PE 
were anticoagulated and prospectively followed for one year. This allowed us to report on mortality, 
recurrencies and bleeding complications for a until now poorly explored lapse of time in patients 
treated. Moreover, this made it possible to find the risk factors for mortality, recurrence and 
bleeding  in the early stages after embolization and later on until one year of the acute PE; to our 
knowledge, this has not been reported by other studies. We demonstrated for the first time that the 
persistence of severe dyspnea in spite of the anticoagulant treatment is a powerful risk factor for 
both recurrence and mortality due to PE, both in the acute and in the late phases of PE. This newly 
described symptom occurs in our series associated to the severity of disease and  shows an additive 
effect to the scintigraphic evaluation of perfusion impairment, in predicting both PE-mortality and 
recurrence. Finally, we systematically performed a 1-year scintigraphic follow-up by predefined (at 
7, 30, 360 days of the diagnosis) controls of patients; this allowed to detect cases of non fatal 
recurrences that otherwise would have passed unrecognized. 
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